Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer

Bladder Cancer Clinical Trial

Official title:

Chemoresection With 4 Weekly Intravesical Instillations Of Mitomycin C Versus Transurethral Resection (TUR) Followed By One Single Immediate Instillation Of Mitomycin C In Single, Small, Papillary Stage Ta, T1 Bladder Tumors: A Prospective Randomized Phase III Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00042887
• Other study ID #: EORTC-30004
• Secondary ID: EORTC-30004
• Status: Terminated
• Phase: Phase 3
• First received: August 5, 2002
• Last updated: September 20, 2012
• Start date: May 2002

Study information

• Verified date: September 2012
• Source: European Organisation for Research and Treatment of Cancer - EORTC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Infusing chemotherapy drugs directly into the bladder may kill more cancer cells. It is not yet known if surgery followed by chemotherapy is more effective than chemotherapy alone in treating bladder cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy alone with that of transurethral resection followed by chemotherapy in treating patients who have bladder cancer.

Description:

OBJECTIVES:

• Compare the efficacy of chemoresection with 4 weekly intravesical instillations of mitomycin vs transurethral resection followed by 1 instillation of mitomycin in patients with low-risk superficial transitional cell carcinoma of the bladder.

• Compare the disease-free survival of patients treated with these regimens.

• Determine the response rate at 6 weeks in patients treated with chemoresection.

• Determine the percent of patients with tumor at 6 weeks treated with transurethral resection.

• Compare the quality of life of patients treated with these regimens.

• Compare the side effects of these regimens in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to disease status (primary vs recurrent) and participating center. Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients undergo chemoresection with intravesical instillation of mitomycin once weekly for 4 weeks.

• Arm II: Patients undergo transurethral resection followed within 1-6 hours by intravesical instillation of mitomycin.

Quality of life is assessed at baseline, at week 1 (arm II only), at week 5 (arm I only), and then at week 6.

Patients are followed at weeks 6 and 19, every 6 months for 3 years, and then annually for 2 years.

PROJECTED ACCRUAL: A total of 1,000 patients (500 per treatment arm) will be accrued for this study within 5 years.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 58
• Est. primary completion date: May 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 80 Years

Eligibility

DISEASE CHARACTERISTICS:

• Cytologically confirmed solitary primary or recurrent papillary transitional cell carcinoma of the bladder

• Ta or T1

• Tumor no greater than 2 cm in diameter

• Negative urine cytology

• No suspicious lesions in bladder requiring biopsy

• No tumors in the prostatic urethra or upper urinary tract

• No prior history of T1 G3 tumors, muscle invasive tumors (T2 or greater), or carcinoma in situ

PATIENT CHARACTERISTICS:

Age

• 80 and under

Performance status

• WHO 0-1

Life expectancy

• Not specified

Hematopoietic

• Not specified

Hepatic

• Not specified

Renal

• Not specified

Other

• HIV negative

• No active intractable or uncontrollable bladder infection

• No urethral strictures that would preclude endoscopic procedures or repeated catheterization

• No prior or concurrent congenital or acquired immune deficiency syndrome

• No other prior or concurrent malignancy except cured basal cell skin cancer or intraepithelial cancer of the cervix

• No prior or concurrent leukemia or Hodgkin's disease

• No concurrent disease for which general anesthesia is contraindicated

• No psychological, familial, sociological, or geographical condition that would preclude study compliance

• Not pregnant or nursing

PRIOR CONCURRENT THERAPY:

Biologic therapy

• More than 12 months since prior BCG vaccine

Chemotherapy

• At least 1 year since prior mitomycin

Endocrine therapy

• Not specified

Radiotherapy

• No prior pelvic radiotherapy

Surgery

• No prior organ transplant

Other

• At least 3 months since prior intravesical treatment

Study Design

Allocation: Randomized, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Drug:
• mitomycin C

Procedure:
• conventional surgery

Locations

Country	Name	City	State
Belgium	Academisch Ziekenhuis der Vrije Universiteit Brussel	Brussels
Belgium	Universitair Ziekenhuis Gent	Ghent
Belgium	Virga Jesse Hospital	Hasselt
Belgium	U.Z. Gasthuisberg	Leuven
Italy	Universita Di Palermo	Palermo
Italy	Ospedale S.S. Annunziata	Savigliano
Netherlands	Academisch Medisch Centrum	Amsterdam
Netherlands	Onze Lieve Vrouwe Gasthuis	Amsterdam
Netherlands	Jeroen Bosch Ziekenhuis	NL'S Hertogenbosch
Netherlands	Daniel Den Hoed Cancer Center at Erasmus Medical Center	Rotterdam
Slovakia	Comenius University School of Medicine	Martin
Turkey	Dokuz Eylul University School of Medicine	Izmir

Sponsors (1)

Lead Sponsor	Collaborator
European Organisation for Research and Treatment of Cancer - EORTC

Countries where clinical trial is conducted

Belgium,  Italy,  Netherlands,  Slovakia,  Turkey,